TSH Biopharm (ROCO:8432) Dividend Payout Ratio: 2.20 (As of Jun. 2026) — 129% Above Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:8432 TSH Biopharm Corp Ltd ROCO:8432
88 GF Score
Price NT$50.80
GF Value NT$71.41
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is TSH Biopharm Dividend Payout Ratio?

TSH Biopharm ROCO:8432 +0.20% 88 Dividend Payout Ratio is 2.20 as of Jun. 2026, which is 129% above its 10-year median of 0.96. GuruFocus rates ROCO:8432 with a GF Score™ of 88/100 and a GF Value™ of NT$71.41 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 445 Drug Manufacturers companies, TSH Biopharm ranks worse than 72.58% on this metric.

The Dividend Payout Ratio is the measure of dividends paid out to shareholders relative to the company's net income. It is calculated as the Dividends per Share divided by the Earnings per Share (Diluted) during the same time period. TSH Biopharm's Dividend Payout Ratio for the months ended in Jun. 2026 was 2.20.

The historical rank and industry rank for TSH Biopharm's Dividend Payout Ratio or its related term are showing as below:

ROCO:8432' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.43   Med: 0.96   Max: 1.83
Current: 0.6

During the past 13 years, the highest Dividend Payout Ratio of TSH Biopharm was 1.83. The lowest was 0.43. And the median was 0.96.

ROCO:8432's Dividend Payout Ratio is ranked worse than
72.58% of 445 companies
in the Drug Manufacturers industry
Industry Median: 0.38 vs ROCO:8432: 0.60

As of today (2026-08-29), the Dividend Yield % of TSH Biopharm is 5.14%.

During the past 13 years, the highest Trailing Annual Dividend Yield of TSH Biopharm was 8.37%. The lowest was 1.90%. And the median was 3.19%.

TSH Biopharm's Dividends per Share for the months ended in Jun. 2026 was NT$2.61.

During the past 12 months, TSH Biopharm's average Dividends Per Share Growth Rate was 23.10% per year. During the past 3 years, the average Dividends Per Share Growth Rate was 12.20% per year. During the past 5 years, the average Dividends Per Share Growth Rate was -0.40% per year. During the past 10 years, the average Dividends Per Share Growth Rate was -3.80% per year.

During the past 13 years, the highest 3-Year average Dividends Per Share Growth Rate of TSH Biopharm was 133.10% per year. The lowest was -16.60% per year. And the median was -4.45% per year.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.

TSH Biopharm (ROCO:8432) Dividend Payout Ratio Explanation

In dividends investing, Dividend Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

TSH Biopharm Dividend Payout Ratio Related Terms

TSH Biopharm Dividend Payout Ratio Historical Data

* Premium members only.

The historical data trend for TSH Biopharm's Dividend Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TSH Biopharm Dividend Payout Ratio Chart

TSH Biopharm Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Dividend Payout Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.47 0.90 1.02 0.43 0.58

TSH Biopharm Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Dividend Payout Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.11 0.00 0.00 0.00 2.20

ROCO:8432 vs ZTS: Dividend Payout Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, TSH Biopharm's Dividend Payout Ratio, along with its competitors' market caps and Dividend Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

TSH Biopharm Dividend Payout Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, TSH Biopharm's Dividend Payout Ratio distribution charts can be found below:

* The bar in red indicates where TSH Biopharm's Dividend Payout Ratio falls into.


ROCO:8432
88GF Score
TSH Biopharm Corp Ltd ROCO:8432
Dividend Payout Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

TSH Biopharm Dividend Payout Ratio Calculation

The Dividend Payout Ratio is the measure of dividends paid out to shareholders relative to the company's net income. It is calculated as the Dividends per Share divided by the Earnings per Share (Diluted) during the same time period.

TSH Biopharm's Dividend Payout Ratio for the fiscal year that ended in Dec. 2025 is calculated as

Dividend Payout Ratio=Dividends per Share (A: Dec. 2025 )/ EPS without NRI (A: Dec. 2025 )
=2.12/ 3.639
=0.58

TSH Biopharm's Dividend Payout Ratio for the quarter that ended in Jun. 2026 is calculated as

Dividend Payout Ratio=Dividends per Share (Q: Jun. 2026 )/ EPS without NRI (Q: Jun. 2026 )
=2.61/ 1.187
=2.20

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Dividend Payout Ratio →
What does a Dividend Payout Ratio of 2.20 mean?
TSH Biopharm (ROCO:8432) has a Dividend Payout Ratio of 2.20 as of Jun. 2026. Dividend payout ratio is the percent of company earnings paid out as dividends. View historical data on TSH Biopharm and its competitors. This is 129% above median its historical median of 0.96. Over the past decade, TSH Biopharm's Dividend Payout Ratio has ranged from 0.43 to 1.83. According to the industry distribution chart, TSH Biopharm ranks #323 out of 445 companies in the Drug Manufacturers industry, placing it in the top 72.6%.
Is TSH Biopharm's Dividend Payout Ratio too high?
TSH Biopharm's current Dividend Payout Ratio of 2.20 is 129% above median its 10-year median of 0.96. Over the past 10 years, this metric has ranged from a low of 0.43 to a high of 1.83. The Drug Manufacturers industry median Dividend Payout Ratio is 0.38. TSH Biopharm's value of 2.20 is 478.9% above this industry median. Based on the distribution chart, TSH Biopharm ranks #323 out of 445 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, TSH Biopharm has a GF Score™ of 88/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does TSH Biopharm's Dividend Payout Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, TSH Biopharm ranks #323 out of 445 companies for Dividend Payout Ratio. This places TSH Biopharm in the lower half of its industry. The industry median Dividend Payout Ratio is 0.38. TSH Biopharm's value of 2.20 is 478.9% above this benchmark. Historically, TSH Biopharm's own Dividend Payout Ratio has ranged from 0.43 to 1.83 over the past decade. While the company's 10-year median is 0.96 vs. the industry median of 0.38, TSH Biopharm has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Dividend Payout Ratio for a Drug Manufacturers company?
The median Dividend Payout Ratio among Drug Manufacturers companies is 0.38, based on 445 companies in the industry. Companies in the top quartile (top 25%) have a Dividend Payout Ratio significantly above this median, while those in the bottom quartile fall well below. However, Dividend Payout Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. TSH Biopharm's current Dividend Payout Ratio of 2.20 is 478.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Dividend Payout Ratio mean?
A high Dividend Payout Ratio can signal that a stock is expensive relative to its fundamentals. Dividend payout ratio is the percent of company earnings paid out as dividends. View historical data on TSH Biopharm and its competitors. For the Drug Manufacturers industry, the median Dividend Payout Ratio is 0.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TSH Biopharm's current Dividend Payout Ratio is 2.20, which is 129% above median its own 10-year median of 0.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TSH Biopharm stock overvalued right now?
Based on GuruFocus' analysis, TSH Biopharm (ROCO:8432) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$71.41, compared to a current price of NT$50.80 — trading 28.9% below its estimated fair value. The current Dividend Payout Ratio is 2.20, which is 129% above median its 10-year median of 0.96 and 478.9% above the Drug Manufacturers industry median of 0.38. TSH Biopharm's overall GF Score™ is 88/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Dividend Payout Ratio calculated?
Dividend Payout Ratio is calculated from a company's financial statements. For TSH Biopharm (ROCO:8432), the current Dividend Payout Ratio is 2.20 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is TSH Biopharm (ROCO:8432) Overvalued in 2026?

Based on GuruFocus' analysis, TSH Biopharm stock appears to be undervalued. The current stock price of NT$50.80 is trading 28.9% below its estimated GF Value™ of NT$71.41. GuruFocus considers TSH Biopharm to be Modestly Undervalued.

Key valuation signals for ROCO:8432:

  • Dividend Payout Ratio: 2.20 (129% above median its 10-year median of 0.96)
  • GF Value™: NT$71.41 vs. price of NT$50.80 (28.9% below fair value)
  • GF Score™: 88/100 with 2 warning signs
  • Industry Position: 478.9% above the Drug Manufacturers median (#323 of 445)

No single metric tells the full story. See the ROCO:8432 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

TSH Biopharm Business Description

Address No.3-1, Park Street, 3rd Floor-1, Nangang District, Taipei, TWN, 115
TSH Biopharm Corp Ltd is engaged in sale of a variety of pharmaceuticals, chemical drugs and engaged in biotechnology services. The company specializes in the development, manufacture, and marketing of branded drugs for chronic diseases. Key therapeutic areas include cardiovascular, central nervous system, gastroenterology, and severe chronic diseases, alongside precision medicine/genetic testing services .The Company's revenue is earned domestically. It earns majority of its revenue from the sale of Lozenges.
88GF Score

Get the complete analysis for ROCO:8432

Dividend Payout Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$50.80
Price
NT$71.41
GF Value